When a patient or their family asks us “what are the chances this will work?” — they deserve a real answer. Not a vague reassurance, not impossible promises, and not the kind of cautious non-answer that leaves people more confused than when they started.

This article is our attempt to provide that real answer for the cancers we most commonly treat at Denvax. We have drawn on current published clinical data, international trial results, and our own clinical observations over more than a decade of delivering immunotherapy to Indian patients.

We want to be transparent about what the evidence shows — including where immunotherapy is transformative, where it provides meaningful but limited benefit, and where the honest picture is more nuanced.

How “Success” Is Defined in Oncology?

Before reading any survival statistics, it is important to understand what they actually measure:

Overall Survival (OS): The percentage of patients alive at a specific timepoint (commonly 1, 3, or 5 years) after starting treatment.

Progression-Free Survival (PFS): The length of time during which a patient’s disease does not worsen. A patient can have excellent PFS without the tumour disappearing entirely.

Objective Response Rate (ORR): The percentage of patients whose tumour reduces by at least 30% in size. This does not capture patients whose cancer is stable (not growing) but not shrinking — who are also benefiting from treatment.

Disease Control Rate (DCR): Combines complete response, partial response, and stable disease. A more complete picture of benefit.

Complete Response (CR): Tumour undetectable on imaging. This is the goal of treatment but not required for meaningful benefit — stable disease with excellent quality of life is a meaningful outcome.

Understanding these definitions matters because a study reporting “30% response rate” sounds modest until you understand that another 30–40% of patients may have stable disease — making the disease control rate 60–70%.

Immunotherapy Success Rates by Cancer Type

Melanoma (Metastatic)

Before immunotherapy: 5-year survival for metastatic melanoma was under 5%.

With immunotherapy (checkpoint inhibitors): 5-year survival rates of 40–52% have been reported in clinical trials with pembrolizumab and ipilimumab/nivolumab combination. This is one of the most dramatic transformations in oncology in the last decade.

Denvax context: Dendritic Cell Therapy for melanoma has shown durable responses in patients not eligible for or not responding to checkpoint inhibitors. For patients with metastatic melanoma, immunotherapy in some form is now considered the first-line approach internationally.

Non-Small Cell Lung Cancer (Stage 3–4)

Before immunotherapy: Median survival for metastatic NSCLC was 10–12 months on chemotherapy.

With immunotherapy (PD-L1 high expression): Pembrolizumab as first-line therapy in patients with PD-L1 ≥50% shows median overall survival exceeding 26 months — more than double the chemotherapy baseline. In some PD-L1 high patients, 5-year survival approaches 30%.

With chemotherapy + immunotherapy combination: Even in patients with lower PD-L1 expression, combining immunotherapy with chemotherapy has improved median OS to 15–22 months compared to 10–13 months with chemotherapy alone.

Denvax context: Lung cancer is one of the most commonly treated conditions at our centre. Dendritic Cell Therapy has produced meaningful disease control and symptom improvement in lung cancer patients, particularly in combination with other agents.

Breast Cancer

Triple-Negative Breast Cancer (TNBC): This is the breast cancer subtype with the fewest targeted treatment options and historically the worst prognosis. Immunotherapy has changed this significantly. Pembrolizumab combined with chemotherapy for metastatic PD-L1 positive TNBC has improved median OS to 23 months compared to 17 months with chemotherapy alone.

HER2+ and Hormone Receptor Positive Breast Cancer: These subtypes have their own targeted therapy options (trastuzumab, CDK4/6 inhibitors, etc.) and the role of immunotherapy is more complementary. Combination approaches are being actively studied.

Denvax context: We have treated a significant number of triple-negative breast cancer patients with Dendritic Cell Therapy, particularly women who have exhausted conventional options or who wish to use immunotherapy alongside chemotherapy to enhance response. The personalised nature of Dendritic Cell Therapy is particularly well-suited to TNBC given the absence of specific targetable receptors.

Colorectal Cancer (MSI-H/dMMR)

Standard colorectal cancer: Conventional checkpoint inhibitors produce modest response rates in most colorectal cancer patients (around 5–15% ORR).

MSI-H/dMMR colorectal cancer: This subset — characterised by microsatellite instability — responds dramatically well to immunotherapy. Pembrolizumab as first-line therapy has produced overall response rates of 45% and progression-free survival significantly superior to chemotherapy. For this subset, immunotherapy is now the recommended first-line approach internationally.

How to know if this applies to you: MSI/dMMR status is determined from a tissue biopsy and should be tested for all colorectal cancer patients. If you have colorectal cancer and have not had MSI testing, we recommend requesting it.

Denvax context: We screen all colorectal cancer patients for MSI/dMMR status at initial consultation. For MSI-H patients, we integrate checkpoint inhibitor strategies. For MSI-stable patients, Dendritic Cell Therapy protocols are designed to overcome the lower immune responsiveness that characterises these tumours.

Kidney Cancer (Renal Cell Carcinoma, Stage 4)

Before immunotherapy: Metastatic kidney cancer had median OS of 13–17 months on targeted therapies.

With combination immunotherapy: Nivolumab + ipilimumab combination for intermediate and poor-risk metastatic kidney cancer has produced median OS of 47 months — nearly four years — with 5-year OS rates of 43%. This compares to 5-year OS of approximately 26% on targeted therapy alone.

Denvax context: Kidney cancer is one of the immunotherapy success stories that most clearly demonstrates the potential for long-term disease control. We have treated Stage 4 kidney cancer patients with Dendritic Cell Therapy combined with checkpoint inhibitors with meaningful results.

Bladder Cancer (Advanced/Metastatic)

Checkpoint inhibitors: are now approved first-line for cisplatin-ineligible patients with PD-L1 positive advanced bladder cancer. Atezolizumab and pembrolizumab both have approval in this setting.

Response rates: Overall response rates of 23–29% in first-line PD-L1 positive patients, with a subset achieving durable complete responses.

Denvax context: Bladder cancer patients who cannot tolerate cisplatin-based chemotherapy — a substantial number, as many are elderly or have compromised kidney function — benefit significantly from immunotherapy-first approaches.

Cervical Cancer (Advanced)

Pembrolizumab added to chemotherapy for first-line treatment of metastatic/recurrent cervical cancer has improved median OS to 28 months compared to 17 months with chemotherapy alone — a 65% improvement in median survival.

This is particularly relevant in India where cervical cancer incidence remains high and many patients present at advanced stages.

Head and Neck Cancers (Squamous Cell Carcinoma)

Pembrolizumab alone or combined with chemotherapy as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma has improved OS compared to the previous standard (EXTREME regimen). In PD-L1 high patients, pembrolizumab alone is now preferred.

Prostate Cancer

Prostate cancer has historically been less responsive to standard immunotherapy. However, Dendritic Cell Therapy (sipuleucel-T was the first FDA-approved cancer vaccine for prostate cancer) has demonstrated survival benefit in metastatic castration-resistant prostate cancer.

Research continues to evolve, with combination approaches (checkpoint inhibitors + hormone therapy, Dendritic Cell Therapy + targeted agents) showing increasing promise.

An Honest Word About Success Rates

Statistics describe populations, not individuals. A 40% 5-year survival rate for metastatic melanoma means that in a group of 100 patients, roughly 40 would be alive at 5 years. It does not tell you whether you will be among them.

What statistics cannot capture is the individual variation driven by tumour biology, immune system health, treatment quality, and combination strategies. Clinical trials also tend to enrol healthier patients than the average cancer population — real-world outcomes can be higher or lower.

At Denvax, we do not quote statistics to reassure patients. We use them as context. What matters in any individual case is the specific biological profile of the tumour, the patient’s immune system status, the quality of the treatment protocol, and the monitoring and response assessment that follows.

The most meaningful question is not “what is the average success rate?” but “what is the likely response rate for my specific cancer, my specific biology, at this stage, with this treatment protocol?” That is the question we try to answer for every patient who comes to us.

What Denvax Brings to the Success Rate Equation

Immunotherapy results are not equal across all centres. Success rates depend on:

Protocol quality: Dendritic Cell Therapy is a biological product — the quality of the laboratory process, the antigen preparation, the maturation conditions for the dendritic cells, and the timing and scheduling of infusions all affect potency and response rate.

Patient selection: We do not offer immunotherapy to patients unlikely to benefit from it. Appropriate patient selection improves the observed outcomes in patients who do receive treatment.

Combination strategy: The most sophisticated immunotherapy outcomes come from well-designed combination protocols. We invest in the scientific basis for each patient’s treatment design.

Monitoring and adaptation: A protocol that is monitored closely and adapted based on response will outperform one delivered mechanically regardless of patient response.

Frequently Asked Questions

Q: What is the overall success rate of immunotherapy for cancer?
A: This varies enormously by cancer type, stage, and immunotherapy approach. Response rates range from under 15% for some solid tumours to over 60% for certain cancers like MSI-H colorectal cancer or PD-L1 high lung cancer. The most meaningful answer is specific to your cancer type, stage, and biomarker profile — which is what a consultation with us will establish.

Q: Is immunotherapy more effective than chemotherapy?
A: For specific cancer types and patient profiles, yes — significantly so. For others, a combination of both produces the best results. The comparison is not always meaningful because they work through different mechanisms and are often used together. The relevant question is which approach, or which combination, is best for your specific situation.

Q: Does immunotherapy work better at early stages or later stages?
A: Immunotherapy at earlier stages, when the immune system is more intact and the tumour burden is lower, generally produces the best long-term outcomes. However, Stage 4 patients can and do achieve significant responses. Earlier is generally better, but later still offers meaningful options.

Q: What happens if immunotherapy does not work for my cancer?
A: Not responding to one form of immunotherapy does not mean no immunotherapy will work. Different immunotherapy approaches have different mechanisms, and a patient non-responsive to checkpoint inhibitors may respond to Dendritic Cell Therapy, or vice versa. We discuss the full treatment landscape at consultation.

Q: Are Indian patients getting access to the same immunotherapy success rates as patients in the US or Europe?
A: The biological effectiveness of immunotherapy is the same regardless of geography — the same immune mechanisms operate in Indian patients as in Western patients. What varies is access to quality treatment. At Denvax, we deliver protocols that meet international quality standards at a cost accessible to Indian patients.

Q: What is the success rate of Dendritic Cell Therapy specifically?
A: Published data on Dendritic Cell Therapy shows objective response rates (tumour reduction) of 15–30% across most solid tumour types, with disease control rates (stable + responding) of 50–70% in well-selected patients. These numbers vary by cancer type and are best discussed in the context of your specific situation during consultation.

Talk to Us About Your Specific Case

Aggregate statistics can only tell you so much. The most useful information comes from a direct assessment of your individual case — your cancer type, stage, biomarker profile, prior treatment history, and immune system status.

We invite you to book a consultation at Denvax. We will review your case thoroughly and give you a clear, honest picture of what immunotherapy can realistically offer for your specific situation.

Book a Consultation at Denvax →